BLUE Live signaler | Maksimer profitt med Getagraph.com

SELG 115780 min ago

@ $1.019

Utstedt: 14 feb 2024 @ 15:30

Avkastning: -11.67%

Forrige signal: feb 12 - 18:12

Forrige signal: Kjøp

Avkastning: -3.90 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	7.07M
Gjennomsnittsvolum	8.29M
Markedsverdi	173.43M
EPS	$0 ( 2024-04-03 )
Neste inntjeningsdato	( $-0.470 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.430
ATR14	$0.00200 (0.22%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-01	Colvin Richard A	Buy	199 000	Stock Option (right to buy)
2024-03-01	Colvin Richard A	Sell	6 770	Common Stock
2024-03-01	Vittiglio Joseph	Buy	199 000	Stock Option (right to buy)
2024-03-01	Obenshain Andrew	Buy	650 000	Stock Option (right to buy)
2024-03-04	Obenshain Andrew	Sell	6 095	Common Stock

INSIDER POWER
92.31
Last 95 transactions
Buy: 3 237 593 \| Sell: 214 711

Volum Korrelasjon

Lang: -0.25 (neutral)

Kort: -0.79 (moderate negative)

Signal:(41.481) Neutral

bluebird bio Inc Korrelasjon

10 Mest positive korrelasjoner
ALXO	0.973
YJ	0.949
ORPH	0.947
PMVP	0.946
CSSEP	0.946
KNSA	0.945
NAKD	0.944
GOOD	0.944
IPA	0.943
GSMG	0.942

10 Mest negative korrelasjoner
CPAQ	-0.961
MCAA	-0.958
SCOB	-0.957
LGACU	-0.957
ABGI	-0.957
FICV	-0.957
AGGR	-0.957
LGAC	-0.957
LVRA	-0.955
KAII	-0.955

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

bluebird bio Inc Korrelasjon - Valuta/Råvare

0.00
( neutral )

0.08
( neutral )

0.00
( neutral )

-0.09
( neutral )

bluebird bio Inc Økonomi

Annual	2022
Omsetning:	$3.60M
Bruttogevinst:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2022
Omsetning:	$3.60M
Bruttogevinst:	$-6.48M (-180.15 %)
EPS:	$-3.39

FY	2021
Omsetning:	$3.66M
Bruttogevinst:	$-35.20M (-961.09 %)
EPS:	$-11.89

FY	2020
Omsetning:	$250.73M
Bruttogevinst:	$245.34M (97.85 %)
EPS:	$-9.95

Financial Reports:

No articles found.

bluebird bio Inc

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.